Enisamium Inhibits SARS-CoV-2 RNA Synthesis.
MetadataShow full item record
Elli, S., Bojkova, D., Bechtel, M., Vial, T., Boltz, D., Muzzio, M., Peng, X., et al. (2021). Enisamium Inhibits SARS-CoV-2 RNA Synthesis.. Biomedicines, 9 (9) https://doi.org/10.3390/biomedicines9091254
Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called coronavirus disease 2019 (COVID-19). While control of the SARS-CoV-2 spread partly depends on vaccine-induced or naturally acquired protective herd immunity, antiviral strategies are still needed to manage COVID-19. Enisamium is an inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. In vitro, enisamium acts through metabolite VR17-04 and inhibits the activity of the influenza A virus RNA polymerase. Here we show that enisamium can inhibit coronavirus infections in NHBE and Caco-2 cells, and the activity of the SARS-CoV-2 RNA polymerase in vitro. Docking and molecular dynamics simulations provide insight into the mechanism of action and indicate that enisamium metabolite VR17-04 prevents GTP and UTP incorporation. Overall, these results suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis in vitro.
Amizon, COVID-19, FAV00A, RNA polymerase, SARS-CoV-2, molecular dynamics simulation
ZonMw (10430 01 201 0018)
Wellcome Trust (206579/Z/17/Z)
External DOI: https://doi.org/10.3390/biomedicines9091254
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330091
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com